Publicacións en colaboración con investigadores/as de Hospital Son Llàtzer (17)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

  3. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

  2. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 980-987

2020

  1. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

2019

  1. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

  2. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  2. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

    Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537

2015

  1. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1020-1029

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

  2. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

    Clinical and Translational Oncology, Vol. 14, Núm. 9, pp. 689-697

  3. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

2008

  1. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

    British Journal of Cancer, Vol. 98, Núm. 10, pp. 1608-1613